News
Applications Open for BioBusiness Masterclass 2027!
Are you building a life sciences venture and ready to take the next step?
Are you attending JPM 2027? Get in touch!
Are you a Dutch life sciences or biotech company planning to be in San Francisco for the J.P. Morgan Healthcare Conference in January 2027?
UCANACT secures €800K to advance brain-computer communication technology
Utrecht, September 15, 2026 – UCANACT, a Dutch neurotechnology startup developing brain-computer interface technology for people with motor disabilities, has secured €800,000 in pre-seed funding.
Biotech Booster 2027 opening soon
After three successful project rounds, the 2027 Biotech Booster round will soon open for pre-applications. For each round, funding is available up to €200.000 for Level 1 projects and €1.9 million for Level 2 projects.
inSteps receives funding from Innovatiefonds Noord-Holland for the development of an AI-driven computer simulation platform for thrombectomy.
inSteps B.V., a spin-out of Amsterdam UMC, has received a convertible loan of €450,000 from the Innovatiefonds Noord-Holland. With this funding, the company will further develop its AI-driven computer simulation platform for thrombectomy.
TargED Announces First Patients Successfully Dosed in Study of TGD001 in Acute Ischemic Stroke
TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for thrombotic diseases, today announced that the first patients have been dosed in a Phase 1b/2a proof-of-concept clinical study evaluatin
Eliminating cancer with light: KWF invests €4 million in first patient study Lumox
Killing cancer cells with light. Does that sound like science fiction? It's not. In fact, KWF Kankerbestrijding has been supporting scientific research at Utrecht University for years to bring this treatment to people.
We're hiring: Communication Coordinator for LifeSciences@Work
Are you passionate about science communication and eager to help innovative life sciences startups grow their impact? LifeSciences@Work is looking for a Communication Coordinator to strengthen our team.
TargED Raises €40.4M Series A2 to Advance First-in-Class Targeted Thrombolytic TGD001
Utrecht, the Netherlands, June 24, 2026 – TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for thrombotic diseases, today announced the second and final closing of its Ser
Cohort 2 BioVenture Builder: Selection process started
Many early‑stage biotech founders get stuck between preclinical validation and investor readiness.